Table 2.

Baseline characteristics of patients with LDL-C ≥ 190 mg/dL receiving high-intensity statin therapy compared to those not receiving high-intensity statin therapy

	Patients receiving high-intensity statin therapy (n= 15,791)	Patients not receiving high-intensity statin therapy (n=33,656)	p-value
Age, y, mean/SD	62.0/12.5	63.0/13.5	<.0001
Male sex, n (%)	6,441 (40.8%)	11,245 (33.4%)	<.0001
Race, n (%)			<.0001
White	9,079 (57.5%)	21,406 (63.6%)
Black	1,293 (8.2%)	2404 (7.2%)
Other	5,410 (34.3%)	9,830 (29.2%)
Practice Region			<0.001
Midwest region	3,022 (19.15%)	7,234 (21.5%)
Northeast region	3,003 (19.03%)	5,274 (15.68%)
South region	7,599 (48.15%)	17,436 (51.83%)
West region	2,158 (13.67%)	3,696 (10.99%)
Insurance type, n (%)			<0.001
Private	8,827 (55.9%)	17,015 (50.55%)
Public	2,279 (14.45%)	5,248 (15.6%)
None	82 (0.5%)	352 (1.05%)
Others/unknown	4,603 (29.15%)	11,040 (32.8%)
Coronary artery disease, n (%)	7,521 (47.6%)	12,352 (36.7%)	<.0001
Diabetes mellitus, n (%)	4030 (25.5%)	6,336 (18.8%)	<.0001
Hypertension, n (%)	11,034 (69.9%)	22,248 (66.1%)	<.0001
Current smoking, n (%)	3,521 (22.8%)	6,601 (20.5%)	<.001
Peripheral artery disease, n (%)	1619 (10.3%)	2,190 (6.5%)	<.0001
Chronic kidney disease, n (%)	843 (5.3%)	1161 (3.5%)	<.0001
Myocardial infarction, n (%)	2,137 (13.5%)	3,464 (10.3%)	<.0001
PCI, n (%)	3,669 (23.2%)	3,945 (11.7%)	<.0001
Stroke, n (%)	2,113 (13.4%)	2,564 (7.6%)	<.0001
Low density lipoprotein (LDL) cholesterol (mg/dL), mean/SD	215.4/27.4	213.3/26.0	<.0001
Patients on alirocumab, n (%)	115 (0.7%)	169 (0.5%)	0.004
Patients on evolocumab, n (%)	167 (1.1%)	281 (0.8%)	0.031
Patients on ezetimibe, n (%)	2,193 (13.9%)	2001 (6.0%)	<.0001

PCI = percutaneous coronary intervention, SD = standard deviation